Amit Bar-Or
University of Pennsylvania
H-index: 108
North America-United States
Top articles of Amit Bar-Or
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Ocrelizumab exposure in relapsing–remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension | Journal of neurology | Ludwig Kappos Anthony Traboulsee David KB Li Amit Bar-Or Frederik Barkhof | 2024/2 |
Long-term Effect of Ofatumumab on Serum Immunoglobulin Levels in Patients with Relapsing Multiple Sclerosis (P9-6.007) | Heinz Wiendl Jerome de Seze Amit Bar-Or Jorge Correale Anne Cross | 2023/10/1 | |
Long-term Efficacy of the Sphingosine 1-Phosphate Receptor Modulator Ozanimod by Age Category in Patients with Relapsing Multiple Sclerosis: Final Results from Two Phase 3 … | Lawrence Steinman Krzysztof Selmaj Giancarlo Comi Amit Bar-Or Douglas Arnold | 2024/4/14 | |
Development and multi-center validation of a fully automated digital immunoassay for neurofilament light chain: toward a clinical blood test for neuronal injury | Clinical Chemistry and Laboratory Medicine (CCLM) | David Wilson Dandan Chan Lei Chang Robert Mathis Inge Verberk | 2024/1/26 |
Development of an LC-MS/MS method to measure sphingolipids in CSF from patients with multiple sclerosis | Molecular Pharmacology | Yadira X Perez-Paramo Dawn Dufield Rathna Veeramachaneni Emily Parkhurst Christopher Harp | 2024/3/1 |
Absolute Lymphocyte Count Around Infections During Phase 3 and Open-label Extension Trials of Ozanimod in Participants with Relapsing Multiple Sclerosis (P10-6.013) | Hans-Peter Hartung Lawrence Steinman Amit Bar-Or James Sheffield Sarah Harris | 2024/4/14 | |
Longer-term (Up to 6 Years) Efficacy of Ofatumumab in People with Recently Diagnosed and Treatment-naive Relapsing Multiple Sclerosis (S31. 003) | Gabriel Pardo Stephen Hauser Amit Bar-Or Ralf Gold Xavier Montalban | 2024/4/14 | |
A multicenter pilot study evaluating simplified central vein assessment for the diagnosis of multiple sclerosis | Multiple Sclerosis Journal | Lynn Daboul Carly M O’Donnell Moein Amin Paulo Rodrigues John Derbyshire | 2024/1 |
Epstein–Barr Virus Strongly Associates With Pediatric Multiple Sclerosis, But Not Myelin Oligodendrocyte Glycoprotein‐Antibody‐Associated Disease | Annals of Neurology | Giulia Fadda Carmen Yea Julia O'Mahony Patrick Waters E Ann Yeh | 2024/2/27 |
B-Cell Depletion and Efficacy Outcomes of Ofatumumab Are Consistent Across Different Body Mass Index Categories: Insights from ASCLEPIOS I and II Trials (P9-6.002) | Anne Cross Stephen Hauser Heinz Wiendl Amit Bar-Or Patricia Coyle | 2024/4/14 | |
Impact of Fenebrutinib Treatment on MRI Outcomes and Cerebrospinal Fluid Penetrance in Multiple Sclerosis: Results from the Phase II FENopta Study (S31. 004) | Amit Bar-Or Michal Dufek Hrvoje Budincevic Jelena Drulovic Mario Habek | 2024/4/14 | |
Long term effects of continuous positive airway pressure treatment of obstructive sleep apnea-hypopnea syndrome in multiple sclerosis patients | Multiple Sclerosis and Related Disorders | Mylene Mazerolle R John Kimoff Sulaiman Khadadah Pierre Duquette Vincent Jobin | 2024/1/1 |
A cross‐sectional study of MRI features and the gut microbiome in pediatric‐onset multiple sclerosis | Annals of Clinical and Translational Neurology | Feng Zhu Yinshan Zhao Douglas L Arnold Amit Bar‐Or Charles N Bernstein | 2024/2 |
A Bayesian factor analysis model for high-dimensional microbiome count data | arXiv preprint arXiv:2404.03127 | Ismaïla Ba Maxime Turgeon Simona Veniamin Juan Joel Richard Miller | 2024/4/4 |
Spinal Cord Leptomenigeal Enhancement as a Marker of Myelitis Severity in Children with MOGAD (S32. 009) | Serenella Bartiromo Cesar Alves Arastoo Vossough Julia O’Mahony Ann Yeh | 2024/4/14 | |
Short‐chain fatty acid producers in the gut are associated with pediatric multiple sclerosis onset | Annals of Clinical and Translational Neurology | Vinicius A Schoeps Xiaoyuan Zhou Mary K Horton Feng Zhu Kathryn E McCauley | 2024/1 |
Concurrent administration of serotonergic antidepressants and ozanimod in participants with relapsing multiple sclerosis from the open-label extension DAYBREAK trial | Multiple Sclerosis Journal | Robert T Naismith Jeffrey A Cohen Amit Bar-Or Giancarlo Comi Krzysztof W Selmaj | 2024/2/1 |
Emerging cerebrospinal fluid biomarkers of disease activity and progression in multiple sclerosis | JAMA neurology | Anne H Cross Jeffrey M Gelfand Simon Thebault Jeffrey L Bennett H Christian Von Büdingen | 2024/4/1 |
Post-COVID Conditions in People with Multiple Sclerosis: A Cross-sectional Multicenter Study (P1-6.002) | Ji Yeon Son Chen Hu Lindsay McAlpine Amit Bar-Or Megan Dahl | 2024/4/14 | |
Deviation From Normative Whole Brain and Deep Gray Matter Growth in Children With MOGAD, MS, and Monophasic Seronegative Demyelination | Neurology | Giulia Fadda Alonso Cardenas de la Parra Julia O'Mahony Patrick Waters E Ann Yeh | 2023/7/25 |
Co-Authors
